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Membranoproliferative glomerulonephritis (MPGN) denotes
a general pattern of glomerular injury that is easily
recognized by light microscopy. With additional studies,
MPGN subgrouping is possible. For example, electron
microscopy resolves differences in electron-dense deposition
that are classically referred to as MPGN type I (MPGN I),
MPGN II, and MPGN III, while immunofluorescence typically
detects immunoglobulins in MPGN I and MPGN III but not in
MPGN II. All three MPGN types stain positive for complement
component 3 (C3). Subgrouping has led to unnecessary
confusion, primarily because immunoglobulin-negative
MPGN I and MPGN III are more common than once
recognized. Together with MPGN II, which is now
called dense deposit disease, immunoglobulin-negative,
C3-positive glomerular diseases fall under the umbrella of C3
glomerulopathies (C3G). The evaluation of immunoglobulin-
positive MPGN should focus on identifying the underlying
trigger driving the chronic antigenemia or circulating
immune complexes in order to begin disease-specific
treatment. The evaluation of C3G, in contrast, should focus
on the complement cascade, as dysregulation of the
alternative pathway and terminal complement cascade
underlies pathogenesis. Although there are no disease-
specific treatments currently available for C3G, a better
understanding of their pathogenesis would set the stage
for the possible use of anti-complement drugs.
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Membranoproliferative glomerulonephritis (MPGN) denotes
a general pattern of glomerular injury characterized by an
increase in mesangial cellularity and matrix with thickening
of glomerular capillary walls secondary to subendothelial
deposition of immune complexes and/or complement
factors, cellular entrapment, and new basement membrane
formation. This pattern of injury is easily recognized by
light microscopy, making the diagnosis of MPGN relatively
straightforward; however, immunofluorescence (IF) and
electron microscopy (EM) resolve differences among MPGN
that have led to the adoption of classification systems to
subgroup MPGN types. Subgrouping is driven by an effort
to better understand this diverse spectrum of diseases under
the presumption that histologically driven subclassification is
reflective of pathogenic similarities, which may have bearing
on directing clinical care.
Applying EM to MPGN resolves electron-dense deposits
relative to the glomerular basement membrane, such as
subendothelial, intramembranous (within the lamina densa),
or both subendothelial and subepithelial. These distinc-
tions are classically referred to as MPGN type I (MPGN I),
MPGN II, and MPGN III, respectively.1–4 Immunofluores-
cence studies to detect proteinaceous deposits in MPGN will
typically reveal immunoglobulins (usually IgG or IgM) in
MPGN I and MPGN III, whereas MPGN II is noteworthy
because of their absence. Although the three MPGN types
stain positive for complement component 3 (C3) consistent
with complement activation, as early as the 1970s it was
observed that C3-positive but immunoglobulin-negative
examples of MPGN I and MPGN III exist.5 Together
with MPGN II, which is appropriately called dense deposit
disease (DDD; reviewed in ref. 6), this group of C3-positive
Ig-negative glomerular diseases has been labeled as C3
glomerulopathies (C3G; Figure 1a).7,8
MPGN-based and C3G-based classifications overlap
because their fundamental perspectives differ: the MPGN
classification is based on EM, whereas the C3G classification
is based on IF microscopy. This overlap is the source of
unnecessary confusion, which we will address in this review
by focusing on the pathophysiology, evaluation, and treat-
ment of these diseases in the context of a simplified
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classification (Figure 1b). Four illustrative cases are also
described. Because the complement cascade is integral to
both MPGN and C3G, we will begin by briefly reviewing
this aspect of innate immunity.
THE COMPLEMENT CASCADE
The complement system is the cornerstone of innate
immunity and its linchpin is C3. The three initiating
pathways of complement activation—the classical (CP),
lectin (LP), and alternative (AP)—all converge in a cascade
manner on this molecule to generate an enzyme complex
called C3 convertase that cleaves C3 into C3a and C3b. C3a
is a potent pro-inflammatory mediator, whereas C3b is
a potent opsonin and a metastable building block from
which additional C3 convertase is made, creating a powerful
amplification loop. Newly generated C3b interacts with
nearby organisms and basement membranes, leading to C3
convertase formation on these surfaces. The association of
C3b with C3 convertase also generates C5 convertase,
initiating the terminal complement complex (TCC), which
terminates in the assembly of the membrane attack complex
(MAC) on cell surfaces leading to cell lysis (Figure 2).
Numerous proteins regulate complement activity to
prevent untoward host damage. Broadly divided into fluid-
phase (proteins in the circulation) and surface-phase
(proteins bound to cell membranes) regulators, these
proteins generally modulate the activity of the C3 and C5
convertases. Examples of fluid-phase regulators include
C1INH (C1 inhibitor) and C4BP (C4-binding protein),
which regulate the CP, and complement Factor H (CFH) and
CFI, which regulate the AP. Examples of surface-phase
complement regulators include membrane-bound proteins
such as CR1 (complement receptor 1, CD35), CD55 (decay-
accelerating factor, DAF), CD46 (membrane cofactor protein,
MCP), CD59, and CRIg (complement receptor of the
immunoglobulin superfamily, also known as VSIG4 (V-set
and Ig domain-containing 4)). Clusterin, vitronectin, and
CFHR1 (complement Factor H-related 1) regulate the TCC.
Several fluid-phase regulators including CFH, clusterin,
vitronectin, CFHR1, and C4BP can also attach to cells and
biomembranes, adding an additional protective layer in these
surfaces to limit active complement products.9
The interaction between complement activators and regu-
lators is complex yet subtle. Perturbation of this balance
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Figure 1 | The classification of membranoproliferative
glomerulonephritis (MPGN) and C3 glomerulopathies (C3G)
can overlap if based on electron microscopic findings.
(a) MPGN-based and C3G-based classifications of glomerular
disease overlap, and are confusing because these two
classifications are driven by different starting points—findings on
electron microscopy (EM) for MPGN and on immunofluorescence
(IF) for C3G. As a general rule, MPGN I and MPGN III are
immune complex diseases characterized by subendothelial or
subendothelial/subepithelial densities resolved by EM; however,
examples of immunoglobulin-negative ‘MPGN I’ and ‘MPGN III’
have been recognized for decades. These types of pathology
fall under the umbrella of C3G and are often called C3
glomerulonephritis (C3GN). MPGN II or dense deposit disease
(DDD, the preferred name) is another type of C3G. (b) A simpler
classification is driven by findings on IF, and classifies MPGN as
immunoglobulin-positive or -negative. The terms MPGN I and
MPGN III are not used, thereby avoiding unnecessary confusion.
Immunoglobulin-positive MPGN suggests classical pathway (CP)
activation and a concerted effort should be made to identify the
underlying cause of antigenemia. Immunoglobulin-negative
C3-positive MPGN is due to dysregulation of the alternative
pathway (AP) and terminal complement complex (TCC). Depend-
ing on the relative degree of dysregulation, the EM picture
can resemble DDD or C3GN. Non-MPGN C3 glomerulopathies
are also seen (see Table 2, light microscopy).
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Figure 2 | The complement cascade is initiated by the classical
pathway (CP, dotted rectangle), alternative pathway (AP,
dashed rectangle), or lectin pathway (LP, not shown). The
principle trigger of the CP, immunoglobulin-complexed antigen,
is the driving force for C3 deposition in immunoglobulin-positive
membranoproliferative glomerulonephritis (MPGN; see Figure 1b).
Two or more adjacent IgG antibodies provide the structural
framework for activation of C1, which cleaves C2 and C4 to
generate C2a and C4b, respectively. These two proteins form the
CP C3 convertase. The AP is constitutively active, a process that is
referred to as ‘tick over’. Binding of complement factor (CF)B, CFD,
and properdin to hydrolyzed C3 or to C3b leads to formation of
the AP C3 convertase C3bBb. This process also generates C3a,
a potent anaphylatoxin. When an additional C3b molecule
associates with C3 convertase, C5 convertase is formed, initiating
the terminal complement complex (TCC) and leading to the
generation of membrane attack complex (MAC). Fluid-phase
regulators of the CP include C4BP and C1INH, and of the AP,
CFH, and CFI (shown in yellow rectangles).
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provides the molecular foundation for understanding C3G.
How dysregulation of the C3 and C5 convertases and
uncontrolled activity of the AP and TCC lead to C3G is
discussed next.
PATHOPHYSIOLOGY
Immune complex–associated MPGN
Immune complex–associated MPGN (MPGN I and III in
Figure 1a) is driven by chronic antigenemia or circulating
immune complexes (Figure 1b). In ‘idiopathic’ or ‘primary’
MPGN, a causal etiology cannot be found, whereas in
‘secondary’ cases the associated systemic disease or infection
is known. As a general rule, the term ‘idiopathic’ MPGN
should be used infrequently as the underlying reason for
antigenemia can be found in most cases.8
Immune complex–associated MPGN in the adult popula-
tion is most commonly due to antecedent hepatitis B or
C viral infection that drives persistent antigenemia and
immune complex formation. In addition to other viruses,
infectious causes of MPGN also include those of bacterial
origin such as shunt nephritis and infective endocarditis,
and protozoal diseases such as malaria and schistosomiasis.
MPGN can also result as a complication of circulating
immune complexes associated with autoimmune diseases
such as mixed cryoglobulinemia, systemic lupus erythema-
tosus, Sjo¨gren’s syndrome, and scleroderma. Finally, deposi-
tion of monoclonal immunoglobulins in the mesangium and
along the glomerular capillary walls is another important
cause of immune complex MPGN, and can occur in the
setting of monoclonal gammopathy of undetermined signi-
ficance, chronic lymphocytic leukemia, low-grade B-cell
lymphomas, and multiple myeloma (Table 1).8,10,11
Immune complexes activate the CP triggering an acute
injury in the glomerular capillaries and mesangium with
influx of inflammatory cells that gives rise to proliferative
glomerular changes. The reparative glomerular response is
characterized by endothelial and mesangial cell generation of
neo-basement membranes, which trap immune complexes,
thus forming double contours. Mesangial expansion also
occurs because of an increase in mesangial cells, infiltration
of mononuclear cells, and increase in mesangial matrix. In
concert, these changes make the glomerular tufts appear
hyperlobulated. The proportion of cells to matrix varies with
disease duration and time. Chronicity is associated with the
development of nodular mesangial sclerosis and well-formed
double contours with a concomitant decrease in cellularity.
C3 glomerulopathy
C3G is caused by dysregulation of the AP and TCC (Figures 2
and 3). Over the past few years, our understanding of this
group of diseases has rapidly advanced largely through
detailed genetic studies of animal models and a few human
families that segregate this type of renal injury. We highlight
three of these familial studies as they provide unique insights
into C3G.
Table 1 | Immunoglobulin-positive MPGN
Antigenic stimulus Associated systemic disease
Infectious Viral: hepatitis B and C; HIV
Bacterial: endocarditis; shunt
nephritis; abscesses
Protozoal: malaria; schistosomiasis
Others: mycoplasma; mycobacterial
Autoimmune diseases Systemic lupus erythematosus
Scleroderma
Sjo¨gren’s syndrome
Mixed cryoglobulinemia
Monoclonal immunoglobulins
and paraproteinemias
MGUS
Leukemias
Lymphomas
Myeloma
Miscellaneous Liver disease—hepatitis; cirrhosis
Carcinoma
Sarcoidosis
Drugs
‘Idiopathic’
Abbreviations: MGUS, monoclonal gammopathy of undetermined significance;
MPGN, membranoproliferative glomerulonephritis.
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Figure 3 |C3 glomerulopathies (C3G) are caused by
dysregulation of the alternative pathway (AP) and terminal
complement complex (TCC). The prototypic example is dense
deposit disease (DDD), in which there must be fluid-phase
dysregulation of the C3 convertase, often with dysregulation of
the C5 convertase. Dysregulation of the C3 convertase results in
increased serum levels of complement factor (CF)I-generated
iC3b, which accumulates in the glomerular basement membrane
as the characteristic sausage-shaped dense deposits. C3b
breakdown products are also detectable in plasma as C3c and
C3d. Some patients with C3G also have elevated serum levels of
sMAC. Why dysregulation of the AP and TCC leads to DDD in
some patients and to C3 glomerulonephritis (C3GN) in others
is not understood at this time. However, genetic evidence
suggests that a contributing factor may be the relative degree
of dysregulation of the C3 and C5 convertases. For example,
in the family described by Martı´nez-Barricarte et al.12, there is
dysregulation of C3 convertase but not of C5 convertase.
Clarifying the differences between DDD and C3GN is likely to be
germane to the treatment of these diseases as the availability of
anti-complement therapies is currently limited to eculizumab, an
anti-C5 monoclonal antibody (shown as a red *) that prevents
cleavage of C5 to C5a and C5b, thereby preventing propagation
of the TCC.
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In 2010, Martı´nez-Barricarte et al.12 identified a small nuclear
family in which a mother and her two identical twin boys
segregated a two-amino-acid deletion in MG7 of C3(D923–
924AspGly). This mutant form of C3 was resistant to cleavage
by C3 convertase, and therefore could not form activated
C3b. However, through the normal ‘tickover’ process, which
forms a hydrolyzed C3 convertase, the mutant C3 protein did
form C3D923924DG convertase. This convertase was capable
of cleaving circulating wild-type C3 translated from the
normal (non-mutated) allele but was resistant to CFH-
mediated regulation. As a consequence, the phenotype in
these three people was one of persistent fluid-phase mutant
C3 convertase activity, and at the level of the renal
glomerulus, the picture was one of classic DDD. The mother
and one twin progressed to end-stage renal disease, which
was treated in the mother with three transplants, the last still
functioning after 3 years, although in the face of micro-
hematuria, proteinuria, and progressing renal insufficiency.
The second twin has not yet progressed to end-stage renal
disease. Importantly, both accelerated decay of the mutant
C3 convertase by CD55 and CD46 cofactor activity for CFI
are not affected by the two-amino-acid deletion, providing
conclusive evidence that DDD in this family results
exclusively from fluid-phase AP dysregulation (Figure 3).
A second genetic cause of C3G was recently reported
by Gale et al.13 These investigators identified two families
segregating autosomal dominant microscopic hematuria.
Both families originated from the Troodos mountain region
of Cyprus, suggesting an ancestral founder effect. Renal
biopsy was remarkable for variable glomerular inflammation
in association with subendothelial and mesangial electron-
dense deposits positive by IF for C3. Genome-wide linkage
analysis localized the genetic abnormality to chromosome
1q31–32, a region that includes CFH and the CFHR genes.
Using multiplex ligation–dependent amplification, the
authors identified a nonhomologous allelic recombination
event that resulted in the duplication of CFHR5 to create
a novel CFHR5 fusion gene.
CFHR5 is a 65-kDa plasma protein that consists of nine
short consensus repeat (SCR) domains. The nonhomo-
logous allelic recombination event in these Cypriotic families
creates a larger CFHR5 protein in which its first two
SCRs are duplicated to generate a genetic rearrangement
that is translated into an 11-SCR novel CFHR5 protein
(CFHR51,2,1,2,3–9). The plasma concentration of CFHR5 is
approximately 3–6mg/ml or B1% that of CFH, and although
its precise physiological role is not known, it does colocalize
with complement in diseased glomeruli and can associate with
surface-bound C3 (C3b) to inhibit C3 convertase activity.14–16
Functional studies with the mutant CFHR51,2,1,2,3–9 protein
showed that it was less effective than wild-type CFHR5 in
associating with surface-bound C3b, suggesting a dominant-
negative mechanism of action.13 This finding also highlights
the importance of CFHR5 in complement processing within
the kidney, a role that is further supported by the identification
of CFHR5 mutations in some patients with DDD.17
The third family was reported by Habbig et al.,18 who
described two siblings of consanguineous parentage with
childhood-onset hematuria and proteinuria. Detailed com-
plement studies showed serum decreases in C3 and CFB,
although C4 was normal and C3d was increased. Renal
biopsy was remarkable for prominent mesangial deposition
of C3 and C5b-9, and by EM there were numerous
osmiophilic mesangial deposits with intramembranous and
subendothelial roundish glomerular basement membrane
deposits. Mutation screening of CFH showed that both
children were homozygous for the deletion of a single amino
acid, lysine, at position 224 (CFH K244). This deletion affects
SCR4 of CFH and leads to defective complement control
by severely reducing cofactor, decay accelerating activity
and C3b binding.19 Cell-binding activity, however, remains
normal. Because the typical linear hyperosmiophilia of
DDD was absent, the authors proposed calling this pattern
of injury C3 deposition glomerulopathy (C3DG).
In aggregate, these familial cases suggest that C3G is a
disease spectrum that is dependent on the level and degree of
dysregulation of the AP and TCC. In most cases of DDD and
C3 glomerulonephritis (C3GN), however, the family history
is negative, making the identification of risk factors, whether
genetic or acquired, a challenge. It is possible, for example,
that allele variants of membrane-bound complement regu-
lators may affect the disease phenotype, a hypothesis that
warrants testing. In addition, more in-depth studies are
needed to determine whether specific biomarkers of comple-
ment activity can be used to differentiate DDD from C3GN
and predict response to therapy. Finally, efforts should
be made to clarify the biological role of CFHR5 and the
other CFHR proteins in normal and disease renal physiology.
EVALUATION AND TREATMENT
Immune complex–associated MPGN
The evaluation of immune complex–associated MPGN
should focus on identifying the underlying triggering disease
in order to begin appropriate disease-specific treatment
(Table 1). The cornerstone of therapy in this setting is
often an anti-cell proliferation agent such as a calcineurin
inhibitor, mycophenolate mofetil, cyclophosphamide, or
rituximab.20 In many patients, evaluation of the complement
system will often show evidence for activation of the CP,
with decreased serum levels of C3 and C4, and an abnormal
CH50. Whether anti-complement drugs will be complemen-
tary to anti-proliferative agents in this setting has not been
explored. In a small subgroup of immune complex–associated
MPGN, it may be impossible to determine the origin of
the deposited Ig. These cases should be labeled ‘idiopathic’
MPGN. There may also be a small subset of immune
complex–associated MPGN that demonstrates concurrent
AP abnormalities. It is important to point out that, in such
cases, the deposition of immune complexes in the glomeruli
drives the disease process, and it is imperative to carry out
investigations to determine the etiology of the deposited
immunoglobulins.
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C3 glomerulopathy
Little data exist on the long-term consequences of C3GN.
Servais et al.21 reported on a series of 19 patients with C3GN.
Median age at onset was 29.9 years (range 7–70 years) and
median follow-up age was 12.3 years (range 0.4–34.0 years).
At the time of the study, three patients had progressed
to end-stage renal disease and required dialysis, whereas six
additional patients had substantial renal dysfunction, with
creatinine clearances of less than 60ml/min. Although these
outcomes are based on limited data, they do suggest that,
although the prognosis for C3GN may be poor, it carries a
better prognosis than DDD. More than half of DDD patients
progress to end-stage renal disease within 10 years of
diagnosis, and when transplanted face the dismal reality of
near-universal disease recurrence leading to a 5-year allograft
failure rate of 50%.22
The outlook for either C3GN or DDD is unlikely to
change until disease-specific treatments become available.
Following a biopsy consistent with C3G, most patients
should be placed on angiotensin II type 1 receptor blockers or
angiotensin-converting enzyme inhibitors to improve renal
dynamics, decrease proteinuria, control blood pressure, and
limit glomerular leukocyte infiltration.22,23 All patients
should undergo targeted studies to evaluate the AP by
measuring serum complement levels (C3, C4, CH50, AH50),
complement breakdown products (C3c and sMAC), and
disease-associated autoantibodies such as C3 nephritic
factors and autoantibodies to CFH and CFB. Genetic testing
is also indicated and, at a minimum, should include CFH,
although several other genes have also been implicated in
C3GN and DDD.6,24 Mutations in CFH are also associated
with atypical hemolytic uremic syndrome, where they tend to
cluster in the last two SCRs of the protein and affect its ability
to regulate cell membrane–bound C3 convertase.25
The pathophysiology of C3G suggests that a number of
different treatments should be considered. For example, in
the family described by Habbig et al.,18 CFH replacement
is likely to be beneficial. It is possible that additional CFH
may also help in the Cypriotic form of C3GN. Importantly,
although CFH replacement is currently available only
through plasma exchange, pharmaceutical preparations may
be available for therapeutic use in the near future.26,27 It is
equally clear, however, that exogenous CFH would be of
no benefit to DDD patients with the C3D923DG mutation
reported by Martı´nez-Barricarte et al.,12 as the mutant C3
convertase is CFH resistant. For these patients, specific
treatment options that restore C3 convertase control, impair
C3 convertase activity, or remove C3 breakdown products
from the circulation are required but remain to be developed.
The benefit of targeting MAC is more difficult to assess,
as the role of C5 activation and C5 convertase dysregulation
in the pathogenesis of C3G requires further investi-
gation. There are, however, C3GN patients with elevated
plasma levels of sMAC who would be predicted to benefit
from eculizumab, a monoclonal antibody that blocks C5
activation (and therefore MAC production) and is approved
for the treatment of paroxysmal nocturnal hemoglobinuria
(Figure 3).28 Although eculizumab also appears to be a
very effective therapy for atypical hemolytic uremic syn-
drome,29 its use in C3GN patients needs careful consid-
eration. Certainly, it seems unlikely that patients such
as those reported by Martı´nez-Barricarte et al.12 would
gain much benefit from C5-inhibiting strategies, except
perhaps during secondary triggers of complement activation
(such as infections) that may lead to acute disease
exacerbation.
ILLUSTRATIVE CASES
Case 1
Case 1 showed an MPGN pattern on LM (Figure 4). By IF,
there was predominant IgM and C3 staining in the mesan-
gium and capillary walls. There was also staining for both
Figure 4 |Membranoproliferative glomerulonephritis (MPGN) secondary to hepatitis C. (a) Light microscopy (LM) shows MPGN
with mesangial and endocapillary proliferation and thickened capillary walls with double contour formation (periodic acid–Schiff  20).
(b–e) IF microscopy shows mesangial and capillary wall staining for IgM, C3, and kappa and lambda light chains ( 40). (f) Electron
microscopy (EM) shows subendothelial deposits (white arrows) with double contour formation (black arrows) ( 13,500).
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kappa and lambda light chains. EM studies showed sub-
endothelial deposits with double contour formation. Further
evaluation confirmed hepatitis C infection. Diagnosis: mem-
branoproliferative glomerulonephritis secondary to hepatitis C.
Case 2
Case 2 showed an MPGN pattern on LM (Figure 5). A small
cellular crescent was also noted. IF studies showed staining
for IgG, C3, and kappa light chains along the capillary walls;
lambda light chains were negative. EM studies show sub-
endothelial deposits with double contour formation. Further
evaluation showed monoclonal IgG kappa on immunofixa-
tion studies and 5% plasma cells on bone marrow biopsy.
Diagnosis: membranoproliferative glomerulonephritis secon-
dary to monoclonal IgG kappa.
Case 3
Case 3 showed an MPGN pattern on LM (Figure 6). IF studies
were strongly positive for C3 in the mesangium and along
capillary walls, but were negative for IgG, IgM, IgA, C1q,
and kappa and lambda light chains. EM studies showed
numerous subendothelial and mesangial deposits with double
contour formation. A few intramembranous and occasional
subepithelial deposits were also noted. Evaluation of the
AP identified antibodies to Factor H. Diagnosis: C3GN:
membranoproliferative glomerulonephritis secondary to AP
dysfunction caused by anti-Factor H antibodies.
This case is noteworthy because the differential diagnosis
of C3GN includes postinfectious GN, particularly the
so-called resolving/healing postinfectious GN characterized
by the presence of subepithelial humps (Table 2). The absence
of any history of infection anteceding the development of
GN, the bright C3 staining, and the absence of immunoglo-
bulins on IF should raise the possibility of C3GN. EM is also
helpful in that C3GN typically shows large subendothelial
and mesangial deposits; intramembranous and subepithelial
deposits were also often noted. The deposits are lighter and
have a fuzzy lobular appearance as compared with the darker
and sharper immunoglobulin-containing deposits of post-
infectious GN.
Case 4
Case 4 showed an MPGN pattern on LM (Figure 7). IF studies
were positive for C3 in the mesangium and along capillary
walls, but negative for IgG, IgM, IgA, C1q, and kappa and
lambda light chains. EM studies showed dense deposits along
Figure 5 |Membranoproliferative glomerulonephritis (MPGN) secondary to monoclonal immunoglobulins. (a) Light microscopy (LM)
shows an MPGN with mesangial and endocapillary proliferation and thickened capillary walls with double contour formation. A small
cellular crescent is also noted (periodic acid–Schiff  40). (b–e) Immunofluorescence (IF) microscopy shows mesangial and capillary wall
staining for IgG, C3, and kappa light chains, but is negative for lambda light chains ( 40). (f) Electron microscopy (EM) shows small
subendothelial deposits (white arrow) with double contour formation (black arrows;  3400).
N
Figure 6 |C3 glomerulonephritis (C3GN). (a) Light microscopy
(LM) shows membranoproliferative glomerulonephritis (MPGN)
with thickened capillary walls and double contour formation
(periodic acid–Schiff  20). (b) Immunofluorescence (IF)
microscopy shows strong capillary wall staining for C3 ( 40).
(c, d) Electron microscopy (EM) shows large subendothelial
deposits (white arrows), occasional subepithelial deposit (thick
black arrow) with double contour formation (thin black arrows)
(N, neutrophil) (c  1650, d  4200).
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the glomerular basement membranes and in the mesangium,
and complement studies identified high titers of C3 nephritic
factors. Diagnosis: dense deposit disease.
CONCLUSION
MPGN refers to a pattern of glomerular injury that is easily
recognized by light microscopy. With EM, differences in
electron-dense deposition can be resolved, which are
classically referred to as MPGN I, MPGN II (more
appropriately called DDD), and MPGN III. IF typically
detects immunoglobulins in MPGN I and MPGN III, but not
in DDD, although all three MPGN types stain positive for C3.
Recently, immunoglobulin-negative MPGN I and MPGN III
have become increasingly recognized. Together with DDD,
immunoglobulin-negative C3-positive glomerular diseases
fall more appropriately under the umbrella of C3G.
Immunoglobulin-positive MPGN is driven by chronic
antigenemia or circulating immune complexes, and evalua-
tion should focus on identifying the underlying trigger in
order to begin disease-specific treatment. The cornerstone of
therapy is often an anti-cell proliferation agent, although in
many patients evaluation of the complement system will
show evidence for activation of the CP, with decreased serum
levels of C3 and C4, and an abnormal CH50. The evaluation
of C3G, in contrast, should focus on the alternative
complement cascade. Dysregulation of the AP and TCC
underlies pathogenesis, although the differences that lead to
either a DDD or C3GN pattern of injury are not understood.
The concept of anticomplement therapy as a disease-specific
treatment for the C3G will require better characterization of
this group of diseases.
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